Compared with DTC, ATC/PDTC are characterized by an elevated tumor mutation burden, higher programmed death ligand 1 (PD-L1) levels, and increased neoangiogenesis (VEGFR/FGFR signaling) (7,16–22), suggesting that they may be sensitivity to immune checkpoint and neoangiogenesis inhibitors. The gene discussed is CD274; the disease is neoplasm.